Ignite Creation Date:
2025-12-24 @ 10:45 PM
Ignite Modification Date:
2025-12-30 @ 10:35 AM
Study NCT ID:
NCT00440635
Status:
COMPLETED
Last Update Posted:
2013-04-16
First Post:
2007-02-26
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma
Sponsor:
Janssen-Cilag International NV
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2004-01
Start Date Type:
None
Primary Completion Date:
None
Primary Completion Date Type:
None
Completion Date:
2006-10
Completion Date Type:
ACTUAL
First Submit Date:
2007-02-26
First Submit QC Date:
None
Study First Post Date:
2007-02-27
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2013-04-15
Last Update Post Date:
2013-04-16
Last Update Post Date Type:
ESTIMATED